Back to top
more

Rani Therapeutics (RANI)

(Delayed Data from NSDQ)

$6.68 USD

6.68
42,066

+0.12 (1.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.69 +0.01 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Rani Therapeutics Holdings, Inc. [RANI]

Reports for Purchase

Showing records 1 - 20 ( 43 total )

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/25/2024

Company Report

Pages: 4

Dropping Coverage; Acquisition by Pathos AI Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 10.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/25/2024

Company Report

Pages: 6

Our Takes from Positive RT-111 Data; 2023 Financials; Lowering PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 25.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/06/2024

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/06/2024

Company Report

Pages: 12

RaniPill Delivers in 3rd Ph1 w/ Stelara Biosim; Mgmt Webinar on Feb. 8 @ 11A ET

Provider: Wedbush Securities Inc.

Analyst: ANDERSON R

Price: 25.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/30/2024

Daily Note

Pages: 15

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/30/2024

Daily Note

Pages: 5

Rani Therapeutics Management Access Webinar Invite - Feb. 8, 2024 at 11AM ET

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 10.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/09/2023

Company Report

Pages: 5

Near-Term RaniPill- Catalysts Ahead; 3Q23 Financials; Lowering PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/09/2023

Company Report

Pages: 8

Q3: Focusing on RT-102, RT-111, RaniPill HC Manufacturing; Runway into 2025

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/02/2023

Company Report

Pages: 5

Strategic Update Extends Runway Through Key Inflection Points; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/26/2023

Company Report

Pages: 5

Mounting Data Supports Favorable RaniPill- Safety Profile; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/23/2023

Company Report

Pages: 4

Humira Reliably Delivered Via Oral RaniPill- in Canine Model; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

09/20/2023

Company Report

Pages: 5

RT-111 Phase 1 Trial Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

09/08/2023

Company Report

Pages: 4

Successful Delivery Via Next-Gen, High-Capacity RaniPill; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/17/2023

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/16/2023

Company Report

Pages: 8

Q2: RT-102 RT-111 Become the Focus for 2023, Celltrion Partnership Expansion

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/14/2023

Company Report

Pages: 6

RaniPill to Enter Phase 2 in 2H23; 2Q23 Financials; Modulating PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

06/06/2023

Company Report

Pages: 4

Humira Biosimilar Celltrion Deal De-Risks RT-105 Strategy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/11/2023

Daily Note

Pages: 20

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/11/2023

Company Report

Pages: 8

Q1:23: Continuing to Progress Through Execution Year, Catalysts Ahead in 2024

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/11/2023

Company Report

Pages: 5

Clinical-Stage Pipeline Beefs Up in 2023; 1Q23 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party